OS Therapies (NYSEAMERICAN:OSTX) Earns “Buy” Rating from D. Boral Capital

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock.

OS Therapies Stock Down 3.1%

OS Therapies stock opened at $1.23 on Wednesday. The company’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.63. OS Therapies has a twelve month low of $1.12 and a twelve month high of $2.57. The company has a market cap of $48.62 million, a PE ratio of -1.24 and a beta of -2.98.

OS Therapies (NYSEAMERICAN:OSTX) last posted its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter. As a group, sell-side analysts expect that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Trading of OS Therapies

Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new stake in shares of OS Therapies in the 3rd quarter worth about $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the 3rd quarter worth about $40,000. Ground Swell Capital LLC purchased a new position in shares of OS Therapies during the 3rd quarter worth about $40,000. Bridgeway Capital Management LLC purchased a new position in shares of OS Therapies during the 2nd quarter worth about $47,000. Finally, Jane Street Group LLC purchased a new stake in OS Therapies in the 4th quarter valued at about $39,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.